How Combining Best-Of-Breed Technology And Services Can Ensure Commercial Success For Cell And Gene Therapies

Many cell and gene therapies (CGTs) face commercial failure despite clinical success, primarily due to inflexible and costly manufacturing processes. Rigid, "jack of all trades" automation platforms often fall short, forcing developers to compromise on their specific process needs. This article argues for a "best-of-breed" approach, where therapy developers select and integrate the most effective individual technologies and expert services for their unique workflows. This ensures greater control, flexibility, and efficiency, addressing key manufacturing bottlenecks.

To find out how this adaptable strategy can make CGTs commercially viable, read the full article.